ArticleEnvironmental research2026
Drinking water arsenic, urinary arsenic biomarkers, and cognitive impairment in the REGARDS study.
Article in Environmental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThere are several pathways by which inorganic arsenic (iAs) exposure can affect cognition among adults. Few epidemiologic studies evaluate iAs in water and inter-individual differences in urinary arsenic toxicokinetics. We aimed to estimate the association between individual-level urinary arsenic biomarkers, county-level iAs in drinking water, and cognitive impairment in a cohort of Black and White Americans.
methodsWe evaluated the association between county-level iAs in water and urinary iAs metabolites with incident cognitive impairment in REasons for Geographic and Racial Differences in Stroke (REGARDS). Participants were linked to county-level concentrations of arsenic in public water (n = 15,516) and county-level probabilities of private well arsenic exceeding 10 μg/L (n = 20,448). In addition, urinary concentrations of iAs, monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA) were measured in a subset of participants (n = 1,013). Cognitive impairment was determined by the Six Item Screener (SIS) and the Enhanced Cognitive Battery (ECB). We used multivariable logistic regression to estimate odds ratios.
resultsApproximately 9 % of participants in REGARDS developed incident cognitive impairment on the SIS over 10 years of follow-up. County-level public water iAs concentrations and private well iAs probabilities were not associated with increased odds of cognitive impairment. Higher concentrations of MMA (OR: 1.74 [95 % CI: 1.22, 2.49]) and iAs (OR: 1.58 [95 % CI: 1.12, 2.22]) in urine were associated with greater odds of cognitive impairment on the SIS. Results for the ECB were similar.
conclusionsiAs exposure may be associated with cognitive impairment. Our findings highlight the importance of considering multiple measures of iAs exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.